EDA2R Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA565878-Each-of-1 | In Stock | ₹ 49,439.50 |
PIPA565878 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,439.50
GST (18%): ₹ 8,899.11
Total Price: ₹ 58,338.61
Antigen
EDA2R
Classification
Polyclonal
Conjugate
Unconjugated
Gene
EDA2R
Gene Alias
9430060M22Rik; ectodysplasin A2 isoform receptor; ectodysplasin A2 receptor; EDA2R; EDA-A2 receptor; EDAA2R; EDA-A2R; RGD1564025; Tnfrsf27; Tumor necrosis factor receptor superfamily member 27; tumor necrosis factor receptor superfamily member XEDAR; UNQ2448/PRO5727/PRO34080; X linked ectodysplasin receptor; Xedar; X-linked ectodysplasin-A2 receptor
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
60401
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunocytochemistry
Concentration
0.05 mg/mL
Formulation
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2
Gene Accession No.
Q9HAV5
Gene Symbols
EDA2R
Immunogen
Recombinant Human EDA2R
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Immunogen sequence: CQENEYWDQWG RCVTCQRCGP GQELSKDCGY GEGGDAYCTA CPPRRYKSSW GHHKCQSCIT CAVINRVQKV NCTATS Highest antigen sequence identity to the following orthologs - mouse 86%, rat 88%
- X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2)
- Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain
- Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappa-B and JNK pathways
- Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis
- The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.